Japanese biotech firm Rakuten Medical is putting most of its resources into bringing its photoimmunotherapy cancer treatment to the United States, where it is running Phase 3 trials and aims for an FDA submission in 2028.
Rakuten Medical seeks US approval for light-based cancer treatment
Japanese biotech firm Rakuten Medical is putting most of its resources into bringing its photoimmunotherapy cancer treatment to the United States, where it is running Phase 3 trials and aims for an FDA submission in 2028.
Monitoring item. The full text is not distributed. Extract and source below.